GSK1521498 Alcohol Interaction Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-13

Study Completion Date

2011-09-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to assess the safety and tolerability of GSK1521498 in combination with alcohol and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together. The study will also determine whether GSK1521498 will have an effect on alcohol liking and consumption.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brief Alcohol Intervention and mHealth Booster for Suicidal Adolescents

NCT03607318

Alcohol Drinking Suicide, Attempted Adolescent Behavior

COMPLETED NA

Supporting Women in the UK Armed Forces Who Consume Alcohol at an Increased Risk: Refining the DrinksRation Platform

NCT05970484

Alcohol Abuse Alcohol Drinking Alcohol Use Disorder

UNKNOWN NA

Examining Alcohol Consumption, Perceptions, and User Experience of Alcohol Moderation Strategies

NCT04286867

Alcohol Abuse Alcohol Use Disorder Alcohol Abuse, Episodic

COMPLETED PHASE1/PHASE2

Alcohol and Cannabis Concentrates Co-Administration

NCT05999344

Alcohol Use Disorder Cannabis Use

COMPLETED NA

Cannabis' Impact on Alcohol Consumption

NCT05389930

Alcohol Drinking Cannabis Use Cannabis +1 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is to test a new drug which may be used for treating alcohol addiction. The drug works by inhibiting the effects of messenger molecules called opioids. These opioids are naturally produced within the human body, and are involved in controlling how much alcohol we drink and the pleasure we get from drinking alcohol. We believe that GSK1521498 might be effective in the treatment of alcohol addiction because it is well known that drugs working on similar binding sites in the brain reduce the pleasure we get from drinking alcohol. As alcohol can effect the way that a drug is metabolised in the body, The investigators need to determine that it is safe to take GSK1521498 in combination with alcohol. and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together. The study will also determine whether GSK1521498 will have an effect on alcohol liking and consumption.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GSK1521498 & alcohol

GSK1521498 20 mg and alcohol (0.5g/kg ethanol mixed with orange juice)

Group Type EXPERIMENTAL

GSK1521498

Intervention Type DRUG

GSK1521498 20 mg administered with alcohol to determine PK/PD interactions

GSK1521498 & orange juice

GSK1521498 20 mg and orange juice approximately matching alcoholic beverage for volume and colour

Group Type EXPERIMENTAL

GSK1521498

Intervention Type DRUG

GSK1521498 20 mg administered with alcohol to determine PK/PD interactions

Placebo & alcohol

Placebo and alcohol (0.5g/kg ethanol mixed with orange juice)

Group Type EXPERIMENTAL

Placebo

Intervention Type OTHER

Placebo

Placebo & orange juice

Placebo and orange juice approximately matching alcoholic beverage for volume and colour

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK1521498

GSK1521498 20 mg administered with alcohol to determine PK/PD interactions

Intervention Type DRUG

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy male or female between 21 and 55 years of age inclusive.
* within 20% normal weight for height and body build.
* A female subject of child-bearing potential must use one of the contraception methods listed in the protocol prior to the start of the study until at least 14 days after receiving the last dose of study medication.
* Male subjects must agree to use one of the contraception methods listed in the protocol from the time of the first dose of study medication until at least 5 days after receiving the last dose of study medication.
* History of regular alcohol consumption within 6 months of study.
* No recent changes in patterns of alcohol consumption.
* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria

* A positive test for HIV, Hep B or Hep C.
* Current or chronic history of liver disease.
* Current or chronic history of neurological disorders.
* Subjects with previous or current psychiatric history.
* Past history of DSM-IV alcohol dependence or abuse.
* Binge drinking more than once a week (\>5 standard drinks in one session is a binge).
* Currently trying to quit alcohol.
* Positive urine screen for amphetamines, barbiturates, cocaine, opiates, cannabinoids or bezodiazepines at screening.
* Regular consumption of \>450mg caffeine per day (an average cup contains about 75mg).
* Heavy smokers, defined as those who smoke \>10 cigarettes a day. Also those who cannot abstain during the admission period.
* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 14 days prior to the first dose of study medication.
* Pregnant or lactating females.
* QTcB or QTcF \>450msec.
* Participated in a clinical trial and has received an investigational product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product.
* Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56 day period.

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Austin, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.